Skip to main content
SpringerLink
Log in

Adipose tissue hormones

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

It is now widely accepted that white adipose tissue (WAT) secretes a number of peptide hormones, including leptin, several cytokines, adipsin and acylation-stimulating protein (ASP), angiotensinogen, plasminogen activator inhibitor-1 (PAI-1), adiponectin, resistin etc., and also produces steroids hormones. This newly discovered secretory function has shifted our view of WAT, which is no longer considered only an energy storage tissue but a major endocrine organ, at the heart of a complex network influencing energy homeostasis, glucose and lipid metabolism, vascular homeostasis, immune response and even reproduction. Virtually all known adipose secreted proteins are dysregulated when the WAT mass is markedly altered, either increased in the obese state or decreased in lipoatrophy. This strongly implicates adiposesecreted products in the ethiopathology and/or complications of both obesity and cachexia. This review discusses the physiological relevance of adipose secretion by focusing on protein and steroid hormones. Regulation of WAT secretion by the major regulatory factors impinging on the adipocytes, i.e. insulin, glucocorticoids, catecholamines and thiazolidinediones (TZD) will be addressed. The rationale for therapeutic strategies aimed at compensating adverse effects resulting from overproduction or lack of a specific adipose secretory product will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosen E.D., Spiegelman B.M. Ppargamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001, 276: 37731–37734.

    Article  CAS  PubMed  Google Scholar 

  2. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 1998, 22: 1145-1158.

    Google Scholar 

  3. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 2001, 60: 329–339.

    Article  CAS  PubMed  Google Scholar 

  4. Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J., Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001, 280: E827–E847.

    CAS  PubMed  Google Scholar 

  5. Björntörp P. Endocrine abnormalities of obesity. Metabolism 1995, 44: 21–23.

    Article  PubMed  Google Scholar 

  6. Masuzaki H., Paterson J., Shinyama H. et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294: 2166–2170.

    Article  CAS  PubMed  Google Scholar 

  7. Cassis L.A., Saye J., Peach M.J. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11: 591–596.

    Article  CAS  PubMed  Google Scholar 

  8. Frederich R.C.J., Kahn B.B., Peach M.J., Flier J.S. Tissuespecific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992, 19: 339–344.

    Article  CAS  PubMed  Google Scholar 

  9. Massiera F., Bloch-Faure M., Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001, 15: 2727–2729.

    CAS  PubMed  Google Scholar 

  10. Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998, 41: 65–71.

    Article  CAS  PubMed  Google Scholar 

  11. Samad F., Uysal K.T., Wiesbrock S.M., Pandey M., Hotamisligil G.S., Loskutoff D.J. Tumor necrosis factor-a is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. USA 1999, 96: 6902–6907.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Alessi M.C., Bastelica D., Morange P. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000, 49: 1374–1380.

    Article  CAS  PubMed  Google Scholar 

  13. Kersten S., Mandard S., Tan N.S. et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 2000, 275: 28488–28493.

    Article  CAS  PubMed  Google Scholar 

  14. Yoon J.C., Chickering T.W., Rosen E.D. et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell Biol. 2000, 20 (14): 5343–5349.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Cook K.S., Min H.Y., Johnson D. et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987, 237: 402–405.

    Article  CAS  PubMed  Google Scholar 

  16. Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc. 2001, 60: 349–356.

    Article  CAS  PubMed  Google Scholar 

  17. Murray I., Sniderman A.D., Havel P.J., Cianflone K. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J. Biol. Chem. 1999, 274: 36219–36225.

    Article  CAS  PubMed  Google Scholar 

  18. Saleh J., Blevins J.E., Havel P.J., Barrett J.A., Gietzen D. W., Cianflone K. Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in rodents. Int. J. Obes. Relat. Metab. Disord. 2001, 25: 705–713.

    Article  CAS  PubMed  Google Scholar 

  19. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43: 1271–1278.

    Article  CAS  PubMed  Google Scholar 

  20. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259: 87–91.

    Article  CAS  PubMed  Google Scholar 

  21. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389: 610–614.

    Article  CAS  PubMed  Google Scholar 

  22. Singh A.H., Liu S., Crombie D.L. et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 2001, 59: 765–773.

    Google Scholar 

  23. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab 2001, 280: E745–E751.

    CAS  PubMed  Google Scholar 

  24. Bastard J.P., Maachi M., Van Nhieu J.T. et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 2002, 87: 2084–2089.

    Article  CAS  PubMed  Google Scholar 

  25. Wallenius V., Wallenius K., Ahren B. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8: 75–79.

    Article  CAS  PubMed  Google Scholar 

  26. Wallenius K., Wallenius V., Sunter D., Dickson S.L., Jansson J.O. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem. Biophys. Res. Commun. 2002, 293: 560–565.

    Article  CAS  PubMed  Google Scholar 

  27. Campfield L.A., Smith F.J., Burn P. The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm. Metab. Res. 1996, 28: 619–632.

    Article  CAS  PubMed  Google Scholar 

  28. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395: 763–770.

    Article  CAS  PubMed  Google Scholar 

  29. Ahima R.S., Flier J.S. Leptin. Annu. Rev. Physiol. 2000, 62: 413–437.

    Article  CAS  PubMed  Google Scholar 

  30. Rayner D.V., Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J. Mol. Med. 2001, 79: 8–20.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue [published erratum appears in Nature 1995, 374 (6521): 479. Nature 1994, 372: 425–432.

    Article  CAS  Google Scholar 

  32. Tartaglia L.A., Dembski M., Weng X. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83: 1263–1271.

    Article  CAS  PubMed  Google Scholar 

  33. Farooqi I.S., Jebb S.A., Langmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341: 879–884.

    Article  CAS  PubMed  Google Scholar 

  34. Clement K., Vaisse C., Lahlou N. et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392: 398–401.

    Article  CAS  PubMed  Google Scholar 

  35. Heymsfield S.B., Greenberg A.S., Fujioka K. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282: 1568–1575.

    Article  CAS  PubMed  Google Scholar 

  36. Ahima R.S., Prabakaran D., Mantzoros C. et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382: 250–252.

    Article  CAS  PubMed  Google Scholar 

  37. Bluher M., Michael M.D., Peroni O.D. et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 2002, 3: 25–38.

    Article  CAS  PubMed  Google Scholar 

  38. Trayhurn P., Hoggard N., Mercer J.G., Rayner D.V. Leptin: fundamental aspects. Int. J. Obes. Relat. Metab. Disord. 1999, 23 (1): 22–28.

    Article  CAS  PubMed  Google Scholar 

  39. Mark A.L., Correia M.L., Rahmouni K., Haynes W.G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J. Hypertens. 2002, 20: 1245–1250.

    Article  CAS  PubMed  Google Scholar 

  40. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13: 84–89.

    Article  CAS  PubMed  Google Scholar 

  41. Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8: 731–737.

    Article  CAS  PubMed  Google Scholar 

  42. Matsuda M., Shimomura I., Sata M. et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J. Biol. Chem. 2002, 277: 37487–37491.

    Article  CAS  PubMed  Google Scholar 

  43. Kubota N., Terauchi Y., Yamauchi T. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277: 25863–25866.

    Article  CAS  PubMed  Google Scholar 

  44. Ma K., Cabrero A., Saha P.K. et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem. 2002, 277: 34658–34661.

    Article  CAS  PubMed  Google Scholar 

  45. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7: 941–946.

    Article  CAS  PubMed  Google Scholar 

  46. Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes. Nature 2001, 409: 307–312.

    Article  CAS  PubMed  Google Scholar 

  47. Kim K.H., Lee K., Moon Y.S., Sul H.S. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 2001, 276: 11252–11256.

    Article  CAS  PubMed  Google Scholar 

  48. Steppan C.M., Lazar M.A. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 2002, 13: 18–23.

    Article  CAS  PubMed  Google Scholar 

  49. Way J.M., Gorgun C.Z., Tong Q. et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor? agonists. J. Biol. Chem. 2001, 276: 25651–25653.

    Article  CAS  PubMed  Google Scholar 

  50. Le Lay S., Boucher J., Rey A. et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem. Biophys. Res. Commun. 2001, 289: 564–567.

    Article  PubMed  Google Scholar 

  51. Savage D.B., Sewter C.P., Klenk E.S. et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50: 2199–2202.

    Article  CAS  PubMed  Google Scholar 

  52. Abel E.D., Peroni O., Kim J.K. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409: 729–733.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, 15 rue de l’Ecole de Médecine, 75006, Paris, France

    Micheie Guerre-Millo

Authors
  1. Micheie Guerre-Millo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Micheie Guerre-Millo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guerre-Millo, M. Adipose tissue hormones. J Endocrinol Invest 25, 855–861 (2002). https://doi.org/10.1007/BF03344048

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344048

Key-words

Search

Navigation